Masitinib is positioned as a treatment of severely symptomatic systemic mastocytosis patients, including the subvariants of indolent and smoldering systemic mastocytosis, who are unresponsive to ...
ERIE, Pa. — A strange thing happened a few years ago when Christine Longnecker, who teaches horseback riding in and around ...
The FDA is looking at five big decision deadlines in the coming three weeks, including two for a CAR-T therapy and another ...